Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942 · View on ClinicalTrials.gov ↗

Study Summary

While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects. This study will compare two currently available approaches to reduce AEX in primary care patients: (1) use of inhaled corticosteroids (ICS) as part of rescue therapy, also known as MART (Maintenance And Reliever Therapy) or PARTICS (Patient Activated Reliever Trigger Inhaled Corticosteriods) therapy - either of these therapies will be called Rescue-Inhaled Corticosteroids or R-ICS pronounced "Ricks," and (2) use of azithromycin (AZ) as a preventive therapy. These treatments will be studied both individually and in combination.

Interventions

  • DRUG Azithromycin
  • DRUG Inhaled corticosteroid (ICS)
  • OTHER Asthma Symptom Monitoring Web-based Application

Study Locations (13)

Colorado

  • DARTNet Institute — Aurora
  • University Colorado-Denver — Aurora

North Carolina

  • University North Carolina — Chapel Hill
  • Atrium Health — Charlotte

Texas

  • JPS Health Network — Fort Worth
  • Kelsey Research Foundation — Houston

Florida

  • AdventHealth — Orlando

Kansas

  • University of Kansas — Kansas City

Massachusetts

  • Reliant Medical Group — Worcester

Missouri

  • University of Missouri — Columbia

New Jersey

  • Rutgers Robert Wood Johnson Medical School — New Brunswick

Trial Details

FieldValue
Enrollment Target 3,200 participants
Start Date 2025-08-01
Est. Completion 2029-11-15
Phase Phase 4

Sponsor

DARTNet Institute

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07052942

The ClinicalTrials.gov registry entry for NCT07052942 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DARTNet Institute, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 3 interventions — of which Azithromycin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07052942 reports 13 study locations spanning 10 distinct geographic areas — top geographies include Colorado, North Carolina, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07052942 about?

NCT07052942 is a clinical study titled "Individualizing Treatment for Asthma in Primary Care (Full Study)". While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long ...

What is the current status of trial NCT07052942?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 3,200 participants. The study started on 2025-08-01. Estimated completion is 2029-11-15.

What conditions does trial NCT07052942 study?

This clinical trial studies the following conditions: Asthma, Asthma Attack, Asthma Exacerbations. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07052942?

The interventions under investigation include: Azithromycin (DRUG), Inhaled corticosteroid (ICS) (DRUG), Asthma Symptom Monitoring Web-based Application (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07052942?

This trial is sponsored by DARTNet Institute, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07052942 being conducted?

This trial has 13 study locations across Colorado, Florida, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial